Nuwellis (NASDAQ:NUWE) Stock Price Up 24.7% – Here’s Why

by · The Markets Daily

Nuwellis, Inc. (NASDAQ:NUWE – Get Free Report) was up 24.7% on Thursday . The company traded as high as $2.85 and last traded at $2.37. Approximately 1,350,812 shares changed hands during mid-day trading, an increase of 5,582% from the average daily volume of 23,774 shares. The stock had previously closed at $1.90.

Analyst Upgrades and Downgrades

Several research analysts have commented on NUWE shares. Wall Street Zen downgraded Nuwellis from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Nuwellis in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Nuwellis has an average rating of “Hold”.

Check Out Our Latest Research Report on Nuwellis

Nuwellis Price Performance

The firm has a market cap of $3.15 million, a price-to-earnings ratio of -0.02 and a beta of -0.19. The firm’s fifty day moving average is $2.23 and its 200-day moving average is $4.52.

Nuwellis (NASDAQ:NUWE – Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of ($17.22) by $17.78. Nuwellis had a negative return on equity of 1,367.63% and a negative net margin of 202.83%.The firm had revenue of $2.22 million during the quarter, compared to analyst estimates of $2.50 million. As a group, equities research analysts anticipate that Nuwellis, Inc. will post -8.17 EPS for the current year.

About Nuwellis

(Get Free Report)

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.

See Also